Mersana starts to lose its shine
The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.
Atyr’s Covid-19 benefit claims raise questions
The group has blamed placebo “overperformance” on a high proportion of less-sick patients.
Hope versus experience in glioblastoma
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Hit and miss obesity data for Rhythm
The rare disease player plans to submit Imcivree in Bardet-Biedl syndrome next year, but Alström syndrome looks like a no-go.
